[Türkçe]
Turkish Society of Cardiology Cardiooncology Bulletin Year: 3 Number: 4 / 2025


Turkish Society of Cardiology
Cardiooncology

President:
Dr. Elif Eroğlu Büyüköner
Coordinator for the
Board of Directors
Dr. Yusuf Ziya Şener

Members
Dr. Kartal Emre Aslanger
Dr. Fatma Nihan Turhan Çağlar
Dr. Uğur Nadir Karakulak
Dr. Ertuğrul Okuyan
Dr. Evin Bozçalı Polat
Dr. Nafia İnan Kardelen Ohtaroğlu Tokdil
Dr. Omaç Tüfekçioğlu
Dr. Demet Menekşe Gerede Uludağ
 


Turkish Society of Cardiology Young Cardiologists Bulletin / "" Ekim 2025 (4)
Issue Summary
A Practical Guide for Assessing and Managing Cardiovascular Risk During Androgen-Deprivation Therapy in Patients with Prostate Cancer (Solanki et al. Cancer. 2024)
Dr. Hakan Gedik

Cardiac Biomarkers in Patients with Prostate Cancer and Cardiovascular Disease Receiving Gonadotrophin Releasing Hormone Agonist vs. Antagonist (Margel et al. Prostate Cancer Prostatic Dis. 2021)
Dr. Hakan Gedik

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients with Prostate Cancer Based on Existence of Cardiovascular Risk (Dragomir et al. J Natl Compr Canc Netw. 2023 )
Dr. Hakan Gedik

Cardiovascular Outcomes After Curative Prostate Cancer Treatment: A Population-Based Cohort Study ( Kjellstadli et al. Frontiers in Oncology. 2023)
Dr. Efe Yılmaz

Circulatory and Prostatic Tissue Lipidomic Profiles Shifts After High-Dose Atorvastatin Use in Men with Prostate Cancer (Raittinen et al. Sci Rep. 2020)
Dr. Efe Yılmaz

Changes in Body Composition and Lipid Profile in Prostate Cancer Patients without Bone Metastases Given Degarelix Treatment: The BLADE Prospective Cohort Study Prostate Cancer and Prostatic Diseases (Palumbo et al. Prostate Cancer Prostatic Dis. 2021)
Dr. Efe Yılmaz

Prevalence and Outcomes Of Atrial Fibrillation İn Patients Suffering Prostate Cancer: A National Analysis in The United States
Dr. Furkan Karahan

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis From HERO Study in Advanced Prostate Cancer (Shore et al. Adv Ther. 2023)
Dr. Furkan Karahan

Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients with Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials (Zhou et al. Clinical Genitourinary Cancer. 2024)
Dr. Furkan Karahan

Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease (Roge et al. Cancers. 2023)
Dr. Mehmet Kemal Sabırlı

Prevalence and Risk Evaluation of Cardiovascular Disease in The Newly Diagnosed Prostate Cancer Population in China: A Nationwide, Multi-Center, Population-Based Cross-Sectional Study (Zhang et al. Chin Med J (Engl). 2024)
Dr. Mehmet Kemal Sabırlı

Risk of Cardiovascular Mortality with Androgen Deprivation Therapy in Prostate Cancer: A Secondary Analysis of The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial (Butler et al. Cancer. 2021)
Dr. Mehmet Kemal Sabırlı
 2025 © Turkish Society of Cardiology.